Enhanced T cell effector activity by targeting the Mediator kinase module.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36356142.
- Also identified by DOI 10.1126/science.abn5647 and PMC identifier 10335827.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T cells are the major arm of the immune system responsible for controlling and regressing cancers. To identify genes limiting T cell function, we conducted genome-wide CRISPR knockout screens in human chimeric antigen receptor (CAR) T cells. Top hits were <i>MED12</i> and <i>CCNC</i>, components of the Mediator kinase module. Targeted <i>MED12</i> deletion enhanced antitumor activity and sustained the effector phenotype in CAR- and T cell receptor-engineered T cells, and inhibition of CDK8/19 kinase activity increased expansion of nonengineered T cells. <i>MED12</i>-deficient T cells manifested increased core Meditator chromatin occupancy at transcriptionally active enhancers-most notably for STAT and AP-1 transcription factors-and increased <i>IL2RA</i> expression and interleukin-2 sensitivity. These results implicate Mediator in T cell effector programming and identify the kinase module as a target for enhancing potency of antitumor T cell responses.
Medical subject headings
- Mediator Complex
- T-Lymphocytes
- Receptors, Chimeric Antigen
- Cyclin C
- Neoplasms